(1) Whether his department has conducted any study to determine health (a) benefits and (b) risks in the use of nebulised hypertonic saline solution for acute bronchiolitis in infants; if not, why not; if so, what are the relevant details; (2) whether his department intends to promote the use of nebulised hypertonic saline solution as the standard treatment to (a) reduce the length of hospitalisation and (b) improve clinical severity score in infants with acute viral bronchiolitis; if not, why not; if so, what are the relevant details; (3) whether he will make a statement on the matter?